A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer
- Conditions
- Advanced Cancer
- Interventions
- Drug: ARRY-334543, EGFR/ErbB2 inhibitor; oral
- Registration Number
- NCT00710736
- Lead Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
- Brief Summary
This is a Phase 1 study during which patients with advanced/metastatic solid tumors will receive investigational study drug ARRY-334543 and capecitabine. Patients will receive increasing doses of study drug in combination with capecitabine in order to achieve the highest dose of study drug possible that will not cause unacceptable side effects. Patients will be followed to see what side effects the combination causes and what effectiveness the combination has, if any, in treating the cancer. Approximately 30 patients from the US and Canada will be enrolled in this study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 29
- Histologically or cytologically confirmed diagnosis of any advanced/metastatic cancer suitable for treatment with capecitabine. Pancreatic cancer is not allowed and patients with gastric or gastroesophageal junction (GEJ) cancer are only eligible if prior treatment did not include a total gastrectomy.
- Target lesions may be in a previously irradiated field only if progression of the lesion has been clearly documented.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2.
- Must be able to take and retain oral medications.
- Additional criteria exist.
Key
- Active concomitant malignancies.
- Uncontrolled or symptomatic brain metastases (if a patient has brain metastases and is on steroids, the steroid dose must be stable for at least 30 days).
- Known dihydropyrimidine dehydrogenase (DPD) deficiency.
- Requiring intravenous (IV) alimentation.
- Known positive serology for the human immunodeficiency virus (HIV), hepatitis B and/or hepatitis C.
- Pregnancy or lactation.
- Chemotherapy, anticancer immunotherapy, monoclonal antibodies or biologics within 21 days prior to first dose of study drug.
- Anti-EGFR and/or ErbB2 small molecule targeted therapy or hormonal anticancer therapy within 14 days prior to first dose of study drug.
- History of any hypersensitivity to or intolerance of capecitabine or any of its components, or to fluorouracil or any fluoropyrimidine therapy.
- Additional criteria exist.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description ARRY-334543 + capecitabine Capecitabine, 5-fluorouracil prodrug; oral - ARRY-334543 + capecitabine ARRY-334543, EGFR/ErbB2 inhibitor; oral -
- Primary Outcome Measures
Name Time Method Characterize the safety profile of study drug in combination with capecitabine in terms of adverse events, clinical laboratory tests and electrocardiograms. Duration of study Characterize the pharmacokinetics (PK) of study drug and capecitabine. Duration of study Establish the maximum tolerated dose (MTD) of study drug in combination with capecitabine. Duration of study
- Secondary Outcome Measures
Name Time Method Assess potential predictive biomarkers of clinical activity for the study drug in combination with capecitabine. Duration of study Assess the efficacy of the study drug in combination with capecitabine in terms of tumor response and changes in serological tumor markers. Duration of study
Trial Locations
- Locations (4)
British Columbia Cancer Agency- Centre for the Southern Interior
🇨🇦Kelowna, British Columbia, Canada
Roswell Park Cancer Institute
🇺🇸Buffalo, New York, United States
University of Colorado Cancer Center
🇺🇸Aurora, Colorado, United States
The Ottawa Hospital Cancer Centre
🇨🇦Ottawa, Ontario, Canada